Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%
Portfolio Pulse from Vandana Singh
Moderna and Merck announced significant success in their Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940) plus Keytruda for resected high-risk melanoma. The combo therapy reduced the risk of developing distant metastasis or death by 65%.
June 05, 2023 | 7:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's Keytruda, in combination with Moderna's mRNA-4157 (V940), demonstrated a 65% reduction in risk of distant metastasis or death in a Phase 2b study for high-risk melanoma.
The successful results from the Phase 2b study show that the combination of Merck's Keytruda and Moderna's mRNA-4157 (V940) has significant potential in treating high-risk melanoma. This success is likely to have a positive impact on Merck's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Moderna's mRNA-4157 (V940) plus Keytruda showed a 65% reduction in risk of distant metastasis or death in a Phase 2b study for high-risk melanoma.
The positive results from the Phase 2b study indicate that the investigational therapy has significant potential in treating high-risk melanoma. This success is likely to have a positive impact on Moderna's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100